复方守宫散治疗消化道恶性肿瘤患者癌因性疲乏的临床研究

发布时间：2018-04-22 13:16

本文选题：复方守宫散 + 癌因性疲乏　；参考：《安徽中医药大学》2017年硕士论文

【摘要】：目的:观察复方守宫散对消化道恶性肿瘤患者癌因性疲乏患者的临床症状及疲乏水平的改善情况,并进行进一步分析;研究复方守宫散对消化道恶性肿瘤患者癌因性疲乏、生活质量的治疗效果;为消化道恶性肿瘤患者癌因性疲乏的治疗提供行之有效的中医治疗方法。方法:选取安徽中医药大学第一附属医院肿瘤科2016年1月开始至2017年1月的住院患者中选取消化道恶性肿瘤癌因性疲乏患者90例,随机分为三组:治疗组、对照组、空白组,每组患者均为30例。复方守宫散治疗组(治疗组),采用积极对症治疗+口服复方守宫散(5g/次,2次/日);复方斑蝥胶囊治疗组(对照组),采用积极对症治疗+口服复方斑蝥胶囊(3粒/次、2次/日);空白对照组(空白组),采用积极对症治疗;三组患者每次疗程均为三周,共观察三个疗程;通过观察三组患者治疗前后Piper疲乏量表、生活质量量表评分、KPS评分和中医症候评分表,对比治疗前后三组的治疗效果。结果:通过对比三组患者治疗前后的KPS评分、Piper疲乏量表评分、生活质量量表评分及中医症候评分表,结果表明:1、治疗后治疗组、对照上述量表评分较治疗后改善;2、治疗组患者症状改善较对照组及空白组更为明显。结论:复方守宫散对于消化道恶性肿瘤CRF患者具有显著的治疗效果,与对照组及空白组相比,治疗组治疗改善更为明显;在治疗过程中,治疗组患者无因不能耐受不良反应而终止研究的情况发生,提示复方守宫散对恶性消化道肿瘤CRF患者的治疗具有良好的安全性,值得我们进行进一步的临床研究。
[Abstract]:Objective: to observe the improvement of clinical symptoms and fatigue level in patients with cancer-induced fatigue in patients with digestive tract malignant tumor, and to study the effect of compound Shukong Powder on carcinogenic fatigue of patients with digestive tract malignant tumor. The effect of quality of life (QOL) on the treatment of cancer-related fatigue in patients with malignant digestive tract tumors. Methods: from January 2016 to January 2017, 90 patients with cancerous fatigue of digestive tract malignant tumor were randomly divided into three groups: treatment group, control group and blank group. There were 30 patients in each group. Compound Shukongsan treatment group (treatment group, positive symptomatic treatment, oral compound Shukongsan 5g / time twice a day, compound cantharidae capsule treatment group (control group, positive symptomatic treatment, oral compound cantharidae capsule 3 granules / day) The control group (blank group) was treated with active symptomatic therapy. Each course of treatment in the three groups was three weeks, and three courses of treatment were observed. By observing the Piper fatigue scale, quality of life scale and TCM symptom scale before and after treatment, the therapeutic effects of the three groups were compared before and after treatment. Results: by comparing the KPS scores of the three groups before and after treatment, the scores of Piper fatigue scale, quality of life scale and TCM symptom scale, the results showed that the treatment group, after treatment, Compared with the control group, the improvement of symptoms in the treatment group was more obvious than that in the control group and the blank group. Conclusion: compound ShukongSan has a significant therapeutic effect on CRF patients with digestive tract malignant tumor, compared with the control group and blank group, the treatment group is better than the control group, in the course of treatment, In the treatment group, there were no terminations due to intolerable adverse reactions, suggesting that compound Shukongsan has good safety in the treatment of malignant digestive tract tumor patients with CRF, and is worthy of further clinical study.
【学位授予单位】：安徽中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R735

【参考文献】